Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Celgen Bio-Pharmaceutical Co. Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter represents the company's current focus at the USPTO. The case is assigned to 1 distinct examiner, which allows for a direct and focused dialogue between the applicant and the examiner.
The prosecution is situated within 1 distinct art unit. This indicates that the technology is highly specialized within the biotechnology sector. Because the portfolio is limited to 1 distinct art unit, the practitioner can focus on the specific examination standards and precedents relevant to that particular department.
XIAO, YAN is the busiest examiner for the portfolio, currently responsible for 1 busiest examiner pending action. As the sole examiner involved in the company's current prosecution, XIAO, YAN will have a significant impact on the eventual outcome of the claims. Understanding the specific examination style of XIAO, YAN is critical.
With 1 pending office action, the prosecution strategy is focused on a single set of requirements. The practitioner can devote resources to addressing the specific concerns raised in the Biotechnology & Pharmaceuticals area. This environment allows for a targeted response to the office action issued by the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XIAO, YAN | 1 | 67.3% | +52.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Celgen Bio-Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yan Xiao has the most, with 1 of Shanghai Celgen Bio-Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
